Introduction: Neointimal hyperplasia (NIH) is a major obstacle to the long term patency of peripheral vascular grafts. The disease has a complex aetiology which is influenced, among other phenomena, by mechanical forces such as shear stresses acting on the arterial wall. Objectives: The aim of this work is to assess the impact of haemodynamic factors in a patient-specific, multi-scale modelling framework developed using computational fluid dynamics (CFD) and mathematical biology, for the quantification of NIH growth. Methods: Simulations were performed on datasets from two femoro-popliteal and one femoro-distal bypass patients. Patient data (imaging and haemodynamics) was obtained from Yale University School of Medicine. In this work, smooth muscle cells and collagen in the vascular tissue were modelled using ordinary differential equations. These were linked to wall shear stress (computed using CFD) through its relationship with nitric oxide and growth factors. Results: Results obtained by simulating the growth via the combined CFD and mathematical biology framework seems to outperform analyses performed with haemodynamic indices (obtained by CFD) alone, enabling to pinpoint the locations of NIH and to achieve quantification of its growth. For instance, when only accounting for the time-averaged wall shear stress in the rigid wall model, luminal narrowing was underestimated by up to 19.3%, while when also accounting for oscillatory behaviour the model was able to reach the amount of occlusion present (as measured in the CT scans), with an average overestimate of 10%. Conclusion: The study presents a patient-specific, multiscale simulation framework to model NIH progression. While a previous version of the model underestimated the occlusion of the lumen due to NIH, the results presented show an improvement in estimating occlusion by accounting for movement of the arterial wall, oscillatory behaviour of shear stress and non-Newtonian properties of blood viscosity.
Introduction: Neointimal hyperplasia (NIH) is a major obstacle to the long term patency of peripheral vascular grafts. The disease has a complex aetiology which is influenced, among other phenomena, by mechanical forces such as shear stresses acting on the arterial wall. Objectives: The aim of this work is to assess the impact of haemodynamic factors in a patient-specific, multi-scale modelling framework developed using computational fluid dynamics (CFD) and mathematical biology, for the quantification of NIH growth. Methods: Simulations were performed on datasets from two femoro-popliteal and one femoro-distal bypass patients. Patient data (imaging and haemodynamics) was obtained from Yale University School of Medicine. In this work, smooth muscle cells and collagen in the vascular tissue were modelled using ordinary differential equations. These were linked to wall shear stress (computed using CFD) through its relationship with nitric oxide and growth factors. Results: Results obtained by simulating the growth via the combined CFD and mathematical biology framework seems to outperform analyses performed with haemodynamic indices (obtained by CFD) alone, enabling to pinpoint the locations of NIH and to achieve quantification of its growth. For instance, when only accounting for the time-averaged wall shear stress in the rigid wall model, luminal narrowing was underestimated by up to 19.3%, while when also accounting for oscillatory behaviour the model was able to reach the amount of occlusion present (as measured in the CT scans), with an average overestimate of 10%. Conclusion: The study presents a patient-specific, multiscale simulation framework to model NIH progression. While a previous version of the model underestimated the occlusion of the lumen due to NIH, the results presented show an improvement in estimating occlusion by accounting for movement of the arterial wall, oscillatory behaviour of shear stress and non-Newtonian properties of blood viscosity. Introduction: In-situ engineering of vascular tissues, starting from a degradable synthetic scaffold, requires an optimal balance between scaffold degradation and neo-tissue formation to maintain mechanical function. Due to their elastomeric properties, bis-urea (BU)-modified supramolecular polymers are attractive biomaterials for vascular tissue engineering 1,2 . The susceptibility of these polymers to enzymatic degradation can be easily tuned by varying the amount of ester groups in the polymer backbone. However, it is unknown if and how the degradation of the polymers affects the degradation of the scaffold and its consequent functional performance. Therefore, this study aims to characterize the mechanical performance during accelerated degradation of vascular scaffolds electrospun from candidate BU materials with varying susceptibility to degradation. Methods: Polycaprolactone-BU (PCL-BU), polycarbonateester-BU (PC(e)-BU), and polycarbonate-BU (PC-BU) were selected as base materials and processed into vascular scaffolds using electrospinning (fiber ø 5 mm; scaffold thickness w500 mm, graft ø 3 mm). Enzymatic degradation was induced by incubating the scaffolds in a lipase solution at concentrations ranging from 10U/ml to 500U/ml at 37 C. Scaffold degradation was evaluated in terms of changes in the chemical properties (differential scanning calorimetry, gel permeation chromatography) and physical properties (scanning electron microscopy, mass loss, scaffold dimensions) at 5 different time points up to 12 days. Functional performance was quantified by means of biaxial tensile tests. Results and Discussion: Large amounts of mass loss (up to 80%) were observed following lipase incubation, remarkably with minimal effect on the chemical properties (i.e., thermal properties and molecular weight) of the remaining material. The fast-degrading PCL-BU became stiffer and the slowdegrading PC-BU became weaker with degradation, whereas PC(e)-BU maintained its mechanical performance. Analysis of fibre diameter, remaining mass, and scaffold dimensions further revealed that enzymatic degradation mainly occurs via surface erosion, but is accompanied by a network collapse in the fast-degrading material and water uptake (resulting in swelling of the material) in the slowdegrading material. Conclusion: Our data show that enzymatic degradation of BU scaffolds occurs via both surface erosion and bulk degradation. The exact degradation mechanism, and thus its consequent functional performance, is governed by the susceptibility of the base material to degradation. References: 1. Kluin et al., Biomaterials, 125:101e117, 2017 2. Brugmans et al., Acta Biomater., 27:21e31, 2015 Herein, we demonstrated a simple and effective technique to construct electrospun 3D fibrous scaffolds for accelerated wound healing using a photocrosslinkable hydrogel based on methacryloylated gelatin (GelMA). We found that the physical properties of the photocrosslinkable hydrogel including water retention, stiffness, strength, elasticity and degradation can be tailored by changing the light exposure time. We further observed that the optimized hydrogel fibrous scaffolds which were soft and elastic could support cell adhesion, proliferation and migration into the whole scaffolds, facilitating regeneration and formation of cutaneous tissues within two weeks. Such tunable characteristics of the fibrous GelMA scaffolds distinguished them from other reported substrates developed for reconstruction of wound defects including glutaraldehyde-crosslinked gelatin or poly (lactic-co-glycolic acid) (PLGA), whose physical and chemical properties were difficult to modify to allow cell infiltration into the 3D scaffolds for tissue regeneration. We anticipate that the ability to become fully cellularized will make the engineered GelMA hydrogel fibrous scaffolds suitable for widespread applications as skin substitutes or wound dressings.
External Applicability of the COMPASS Trial: Analysis of a Screened Population with Peripheral Arterial Disease Undergoing Infrainguinal Revascularisation in North Central London
Mital Desai, Aniqa Tasnim, Yvonne Gleeson, George Hamilton, Janice Tsui UCL/Royal Free London NHS Foundation Trust, UK Introduction: The recently published COMPASS trial has shown that low-dose rivaroxaban twice daily plus aspirin once a day reduced major adverse cardiovascular and limb events compared to aspirin alone in patients with either coronary or peripheral arterial disease (PAD). The aim of the present study was to describe the proportion of patients from a prospective PAD trial screening database who would be eligible for the COMPASS trial. Methods: Patients from the North Central London vascular network with PAD undergoing infrainguinal revascularisation were assessed for eligibility for participation in a multicentre international randomised controlled trial. Clinical records and demographic data of all patients screened were maintained in a prospective database. The COMPASS inclusion and exclusion criteria were applied. In addition, 54 eligible patients declined participation. A total of 407 patients (81.4%) would have been excluded. The "COMPASS-eligible" population only comprised of 18.2% (93/500) patients. Conclusion: COMPASS-eligible patients represent a small fraction (less than a fifth) of PAD patients undergoing infrainguinal revascularisation in a real-world population in North Central London. Although addition of low-dose rivaroxaban has been shown to significantly reduce the incidence of major cardiovascular and limb events, the external applicability of these results to different populations need to be considered.
Results

Exclusion criterion
Numbers Percentage High risk of bleeding 28 5.6 Stroke within 1 month or any history of haemorrhagic or lacunar stroke 11 2.2 Severe heart failure with known ejection fraction <30% or NYHA class III or IV symptoms 28 5.6 Estimated glomerular filtration rate < 15 mL/min 57 11.4 Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy 114
22.8
Known non-cardiovascular disease that is associated with poor prognosis (e.g., metastatic cancer) 8 1.6 History of hypersensitivity or known contraindication for rivaroxaban, aspirin 15 3 Systemic treatment with strong inhibitors of CYP 3A4 as well as p-glycoprotein or strong inducers of CYP 3A4 4 0.8
Any known hepatic disease associated with coagulopathy 2 0.4 Subjects who are pregnant, breastfeeding, or are of childbearing potential, and sexually active 5 1 Concomitant participation in another study with investigational drug 2 0.4 Known contraindication to any study-related procedures 79 15.8
